Clinical and laboratory evaluation of amoxicillin (BRL 2333) in the treatment of urinary tract infections.
Amoxicillin (alpha-amino-p-hydroxybenzyl penicillin) is a new oral semisynthetic penicillin with antibacterial activity similar to that of ampicillin; however, it is more completely absorbed and urinary concentrations are higher. Twenty-seven patients during 28 episodes of urinary tract infection were treated with oral amoxicillin given either as 250- or 500-mg doses. Clinical cure or improvement occurred in 23 of 27 infections (85%); eradication of the responsible organisms occurred in 23 of 26 infections (88%); and both clinical cure or improvement and eradication occurred in 20 of 25 infections (80%). Three infections relapsed. Failure to respond bacteriologically was associated with resistant organisms in two patients and with chronic pyelonephritis (Proteus mirabilis) is one. Concentrations of amoxicillin in serum obtained 2 h after administration were more variable than those previously reported for reasons which were obscure. In vitro studies revealed amoxicillin to be comparable to ampicillin when tested against most gram-negative bacilli; however, in this situation amoxicillin may be more effective than ampicillin against enterococci.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000588:Amines / Q000008:administration & dosage / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy*; D004341:Drug Evaluation; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010400:Penicillin G / Q000494:pharmacology; D010406:Penicillins / Q000008:administration & dosage / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000588:Amines; D010406:Penicillins; D010400:Penicillin G